ASND vs SNY
Ascendis Pharma A/S and Sanofi, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ASND | SNY |
|---|---|---|
| Revenue | €720.1M | €43.6B |
| Net income | €-228.0M | €7.8B |
| Gross margin | 86.8% | 77.2% |
| Net margin | −31.7% | 17.9% |
| Return on equity | — | 10.5% |
| Diluted EPS | −€3.76 | €6.37 |
| Dividend / share | — | €3.92 |
| Payout ratio | — | 61.1% |
| Free cash flow | €-469.8M | — |
| Equity | — | €71.4B |
| Net debt / equity | — | 0.15× |
| Current ratio | 1.04× | 1.09× |
| Revenue CAGR 5y | 153.0% | 3.9% |
| Profit CAGR 5y | — | −8.7% |
SNY bills 60.6× the revenue of ASND, and ASND closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ASND | SNY |
|---|---|---|
| FY2025 | €720.1M | €43.6B |
| FY2024 | €363.6M | €41.1B |
| FY2023 | €266.7M | €37.8B |
| FY2022 | €51.2M | €37.7B |
| FY2021 | €7.8M | €37.8B |
| FY2020 | €7.0M | €36.0B |
| FY2019 | €13.4M | €36.1B |
| FY2018 | €10.6M | €34.5B |
| FY2017 | €1.5M | €35.1B |
| FY2016 | €4.6M | €33.8B |
Net income by year
Bottom line
| Fiscal year | ASND | SNY |
|---|---|---|
| FY2025 | €-228.0M | €7.8B |
| FY2024 | €-378.1M | €5.6B |
| FY2023 | €-481.4M | €5.4B |
| FY2022 | €-583.2M | €8.4B |
| FY2021 | €-383.6M | €6.2B |
| FY2020 | €-419.0M | €12.3B |
| FY2019 | €-218.0M | €2.8B |
| FY2018 | €-130.1M | €4.3B |
| FY2017 | €-123.9M | €8.4B |
| FY2016 | €-68.5M | €4.7B |
Advertisement
AdSense · Rectangle 336×280